fda glp-1 compounding enforcement october 2025 What Patients Need to Know About the Policy Changes Did the FDA Ban Compounded

[85] conducted the first descriptive analysis of the characteristics of Adverse Event Reports (AER) documenting the misuse and abuse potential of semaglutide compared to other GLP-1RAs (e.g., albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and tirzepatide) by analyzing the FDA Adverse Events Reporting System (FAERS) pharmacovigilance data set

Lets go back to the original cases we discussed earlier to put this into perspective

Neurosurgery (2004) 55(6):1430

Mounjaro delays gastric emptying, which may affect absorption of oral medications

I think older people with minimal weight to lose could be more at risk of losing a clinically important amount of lean body mass

Dihexa's safety profile in humans is essentially unknown